Bham Pharma Logo.png
×

The future of clinical trial communications

The Future for Clinical Trial Communications Blog | Medical Communications | Bham Pharma
In the fast-paced world of medical research and drug development, effective communication is paramount. Clinical trials, the critical phase of testing new treatments and potential cures, heavily rely on seamless communication to ensure success. The landscape of clinical trial communications is evolving rapidly, with digital channels, patient-centric approaches, and cutting-edge technologies taking centre stage. In this blog, we will explore the future of clinical trial communications, delving into the transformative trends that are reshaping the way researchers and patients interact throughout the drug development journey.

What is the role of interoperability in digital channels?


In the fast-paced world of medicine, the future is digital, and data holds the key to transformative innovations. However, a major challenge stands in the way: lack of interoperability. The current medical data is isolated with databases, incompatible systems, and proprietary software, creating obstacles to seamless exchange, analysis, and interpretation. This slow-moving flow of information not only hinders medical progress but also restrains cutting-edge technologies like artificial intelligence, big data, and mobile applications from reaching their full potential.

However, by embracing interoperable data and IT systems, we can modify medicine and unravel its full digital potential. Let's explore the possibilities in four important areas:

• Artificial intelligence and big data: The possibilities of AI-powered diagnostics and predictive analytics when data flows seamlessly between healthcare systems

Medical communication: Streamlined data exchange means faster and more accurate information for doctors, leading to improved patient care

• Research: Research efforts can rise steeply when data from various studies can be accessed, analysed, and combined effortlessly

• International cooperation: With interoperability, global collaboration in medical advancements becomes a reality, benefitting patients worldwide.

While traditional communication methods have their merits, the expansion of digital channels in the digital era offers greater accessibility, efficiency, and interactivity in clinical trial communications. Digital platforms alongside traditional methods can ensure more cohesive and efficient communication throughout the trial process.

How does patient-centred communication prioritise patients first?


A patient-centric approach is at the core of modern healthcare, and it's no different when it comes to clinical trials. Recognising patients as active stakeholders, rather than passive subjects, is crucial to the success of any trial. Tailoring communication to meet the unique needs and preferences of patients fosters trust, engagement, and compliance. Inclusive language, easy-to-understand materials, and regular updates play a pivotal role in keeping patients informed and motivated throughout the trial journey. Patient-centered communications empower individuals to make informed decisions about their participation, ultimately contributing to better retention rates and more reliable data.

Two insightful surveys shed light on what patients expect from their healthcare providers. Let's delve into the key findings:

  • They want their thoughts, worries, and expectations taken seriously
  • Understanding the whole person and family influences is important
  • Clear and plain language communication is valued
  • Seeking common ground and partnership in decision-making is crucial
  • An enhanced physician-patient relationship is desired, with approachability and genuine care


What pioneering possibilities do new technologies offer?

 
Advancements in technology have opened exciting possibilities in clinical trial communications. For instance, artificial Intelligence (AI), is transforming the way researchers process and analyse vast amounts of data, leading to more informed decisions. Virtual reality (VR) and augmented reality (AR) are revolutionising patient education, providing immersive experiences that enhance understanding and compliance. Telemedicine and remote monitoring solutions are breaking geographical barriers, allowing patients to participate in trials from the comfort of their homes. These technologies not only optimise efficiency but also improve the overall trial experience for participants.


How can Bham Pharma assist you with clinical trial communications?

 
Bham Pharma is committed to supporting you with effective clinical trial information. Our services include:
  • High-quality regulatory writing for scientific research
  • Development of preclinical and clinical research procedures
  • Review and documentation of study conduct, practices, and results
  • Ensuring compliance with all appropriate regulations
  • Supporting partners in delivering transformative medicines and technologies globally, from molecule to market


The future of clinical trial communications is bright and promising


Embracing digital channels, adopting patient-centric approaches, and harnessing new technologies are all essential steps in advancing medical research. By fostering transparent, informative, and inclusive communication, we can forge stronger partnerships between researchers and patients, propelling us closer to life-changing breakthroughs. Together with the support of Bham Pharma, we can confidently stride into the future of clinical trial communications, working towards a healthier and brighter tomorrow.


References

1. Rosa, C. et al. (2021) ‘Using digital technologies in clinical trials: Current and future applications’, Contemporary Clinical Trials, 100, p. 106219. doi:10.1016/j.cct.2020.106219.

2. Lehne, M. et al. (2019) ‘Why Digital Medicine depends on interoperability’, npj Digital Medicine, 2(1). doi:10.1038/s41746-019-0158-1.

3. Hardman, T.C. et al. (2023) ‘The future of clinical trials and drug development: 2050’, Drugs in Context, 12, pp. 1–11. doi:10.7573/dic.2023-2-2.

4. Little, P. (2001) ‘Preferences of patients for patient centred approach to consultation in primary care: Observational study’, BMJ, 322(7284), pp. 468–468. doi:10.1136/bmj.322.7284.468.

5. Bendapudi, N.M. et al. (2006) ‘Patients’ perspectives on ideal physician behaviors’, Mayo Clinic Proceedings, 81(3), pp. 338–344. doi:10.4065/81.3.338.

6. Courtney, E., Blackburn, D. and Reuber, M. (2021) ‘Neurologists’ perceptions of utilising tele-neurology to practice remotely during the COVID-19 pandemic’, Patient Education and Counselling, 104(3), pp. 452–459. doi:10.1016/j.pec.2020.12.027.

Aarti Chauhan - Medical Writer - Bham Pharma.jpg

Author

Aarti Chauhan
Medical Writer II & Social Media Lead